Furthermore, our study suggests that DRP1 may be a potential therapeutic target for depression and that 20 (S)-Protopanaxadiol may improve the symptoms of depression by modulating DRP1-mediated mitochondrial division. Here, DNM1L is linked to depressive disorder.